

2nd Advance_HTA Capacity Building Workshop

24-25 September 2015

Hotel Mercure Warszawa Centrum, Warsaw – Poland

Agenda

Day 1 - Thursday 24 September, 2015

- 08:30-08:45 Arrival and Registration
- 08:45-09:00 Welcome and Introduction, **Panos Kanavos (LSE)** and **Anna Zawada (AOTM)**
- 09:00-09:15 Opening Note: **Guest speaker** (TBC)
- 09:15-11:15 Session 1: Assessing Value for Money**
- How Can Value for Money Be Assessed?, **John Cairns (LSHTM)** 09:15-09:30
 - Why Do Some Countries Approve a Cancer Drug and Others Don't?, **John Cairns (LSHTM)** 09:30-09:55
 - Policy Reactions 09:55-10:05
- Q&A/Debate 10:05-10:20
- Breakout Session: *Assessing the Value of Cancer Drugs* 10:20-11:00
 - Group Work Results 11:00-11:15
- 11:15-11:30 *Coffee Break*
- 11:30-13:30 Session 2: Using Alternative Methods to Assess Value of New Medical Technologies**
- Using Multiple-Criteria Decision Analysis: Conceptual Framework and Model, **Panos Kanavos (LSE)** 11:30-11:45
 - MCDA Application: Empirical Evidence, **Aris Angelis and Panos Kanavos (LSE)** 11:45-12:10
 - Policy Reactions 12:10-12:20
- Q&A/Debate 12:20-12:35
- Breakout Session: *Case Study* 12:35-13:15
 - Group Work Results 13:15-13:30

13:30-14:00 Lunch

14:00-16:00 Session 3: HTA and Rare Diseases: Assessing the Societal Value of Orphan Drugs

- Particularities of the Orphan Drug Market Access Environment – A Quick Overview, **Elena Nicod (LSE)** 14:00-14:20
- Evidence in Dealing with Orphan Drugs and Policy Recommendations, **Elena Nicod (LSE)** 14:20-14:40
- Policy Reactions 14:40-14:50
- Q&A/Debate 14:50-15:05
- Breakout Session: *Orphan Drugs Coverage in Eastern Europe* 15:05-15:45
- Group Work Results 15:45-16:00

16:00-16:15 Coffee Break

16:15-18:15 Session 4: HTA and Quality of Life Measurement

- Whose Preferences Should Be Used for Decision Making in Health Care?, **Marko Ogorevc (IER)** 16:15-16:30
- Values Sets Comparison and Policy Implications, **Marko Ogorevc (IER)** 16:30-16:55
- Policy Reactions 16:55-17:05
- Q&A/Debate 17:05-17:20
- Breakout Session: *Impact of using various value sets on decision making in health care* 17:20-18:00
- Group Work Results 18:00-18:15

18:15-18:30 Summary and Close of Day 1

Day 2 – Friday 25 September, 2015

08:30-09:00 Arrival and Registration

09:00-09:15 Introduction, **Panos Kanavos (LSE) and Anna Zawada (AOTM)**

09:15-11:15 Session 5: Strengthening and Implementing HTA in Emerging Settings

- The Importance of HTA in Emerging Settings, **Jaime Espin (TBC)** 09:15-09:30
- HTA in Emerging Settings - Mapping Exercise and Toolbox, **Jaime Espin (EASP)** 09:30-09:55
- Policy Reactions 09:55-10:05

	Q&A/Debate	10:05-10:20
	- Breakout Session: <i>Challenges in HTA implementation in Eastern Europe</i>	10:20-11:00
	- Group Work Results	11:00-11:15
11:15-11:30	<i>Coffee Break</i>	
11:30-13:30	Session 6: HTA and Medical Devices	
	- Evaluation of Medical Devices: How Is It Different? Current Practices Across European HTA Agencies, Dimitra Panteli, Sabine Fuchs (TUB)	11:30-11:45
	- Approaching The Evaluation of Different Types of Medical Devices Based on a New Taxonomic Model, Dimitra Panteli, Sabine Fuchs (TUB)	11:45-12:10
	- Policy Reactions, TBC	12:10-12:20
	Q&A/Debate	12:20-12:35
	- Breakout Session	12:35-13:15
	- Group Work Results	13:15-13:30
13:30-14:15	<i>Lunch</i>	
14:15-14:30	Lessons Learnt, Policy Recommendations and Advances in HTA Panos Kanavos (LSE)	
14:30-15:00	Distribution of Certificates and Close of Workshop, Panos Kanavos (LSE) and Anna Zawada (AOTM)	
15:00	<i>Workshop Ends</i>	